EAUI yields 2000000.00% · ABBV yields 3.06%● Live data
📍 EAUI pulled ahead of the other in Year 1
Combined, EAUI + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of EAUI + ABBV for your $10,000?
EAU Technologies, Inc. develops, manufactures, and markets equipment that uses water electrolysis to create non-toxic cleaning and disinfecting fluids for food safety applications and dairy drinking water in the United States. Its products include Primacide A, a disinfecting and sanitizing fluid that kills bacteria, yeast, molds, viruses, and other organisms; Primacide B, an alkaline based cleaner; and Primacide C, which is used to stabilize acid water. The company's fluids are used in commercial food processing, and organic or non-organic agricultural and consumer products that clean, disinfect, remediate, hydrate, and moisturize. It markets its products primarily for food and beverage processing, dairy production and processing, meat and poultry processing, and agricultural grow-out and processing industries, as well as environmental remediation, medical, seafood processing, and grocery store produce and meat departments. The company was formerly known as Electric Aquagenics Unlimited, Inc. and changed its name to EAU Technologies, Inc. in January 2007. EAU Technologies, Inc. was founded in 1998 and is headquartered in Kennesaw, Georgia.
Full EAUI Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.